[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647009":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":42,"centralContacts":46,"locations":52,"responsibleParty":105,"collaborators":11,"id":107,"slug":108,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":11,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":11,"enrollmentInfo":116,"targetDuration":11,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":55,"whyStopped":11,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},{"fullName":5,"class":6},"Regeneron Pharmaceuticals","INDUSTRY",[8,14,17,20,23,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Olatorepatide arm 1","EXPERIMENTAL",null,[13],"Drug: Olatorepatide",{"label":15,"type":10,"description":11,"interventionNames":16},"Olatorepatide arm 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Olatorepatide arm 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Olatorepatide arm 4",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"Olatorepatide arm 5",[13],{"label":27,"type":28,"description":11,"interventionNames":29},"Matching Placebo arm 6","ACTIVE_COMPARATOR",[30],"Drug: Placebo",[32,39],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DRUG","Olatorepatide","Administered per the protocol",[9,15,18,21,24],[38],"HS-20094",{"type":33,"name":40,"description":35,"armGroupLabels":41,"otherNames":11},"Placebo",[27],[43],{"name":44,"affiliation":5,"role":45},"Clinical Trial Management","STUDY_DIRECTOR",[47],{"name":48,"role":49,"phone":50,"phoneExt":11,"email":51},"Clinical Trials Administrator","CONTACT","844-734-6643","clinicaltrials@regeneron.com",[53,67,77,86,95],{"facility":54,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":11},"Diablo Clinical Research - Flourish Research","RECRUITING","Walnut Creek","California","94598","United States","US",{"type":62,"coordinates":63},"Point",[64,65],-122.06496,37.90631,{"lat":65,"lon":64},{"facility":68,"status":55,"city":69,"state":70,"zip":71,"country":59,"countryCode":60,"cosmosGeoPoint":72,"geoPoint":76,"contacts":11},"K2 Medical Research Maitland LLC, Main Office","Maitland","Florida","32751",{"type":62,"coordinates":73},[74,75],-81.36312,28.62778,{"lat":75,"lon":74},{"facility":78,"status":55,"city":79,"state":70,"zip":80,"country":59,"countryCode":60,"cosmosGeoPoint":81,"geoPoint":85,"contacts":11},"Charter Research LLC - The Villages","The Villages","32162",{"type":62,"coordinates":82},[83,84],-81.95994,28.93408,{"lat":84,"lon":83},{"facility":87,"status":55,"city":88,"state":70,"zip":89,"country":59,"countryCode":60,"cosmosGeoPoint":90,"geoPoint":94,"contacts":11},"Clinical Site Partners, LLC DBA Flourish Research","Winter Park","32789",{"type":62,"coordinates":91},[92,93],-81.33924,28.6,{"lat":93,"lon":92},{"facility":96,"status":55,"city":97,"state":98,"zip":99,"country":59,"countryCode":60,"cosmosGeoPoint":100,"geoPoint":104,"contacts":11},"AMR Clinical - Lexington","Lexington","Kentucky","40509",{"type":62,"coordinates":101},[102,103],-84.47772,37.98869,{"lat":103,"lon":102},{"type":106,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100647009","phase-2-study-of-olatorepatide-in-adult-participants-living-with-overweight-or-obesity-without-diabetes-100647009",false,"NCT07685808","Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes","A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1\u002FGIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity","Key Inclusion Criteria:\n\n1. Body Mass Index (BMI) ≥30.0 kg\u002Fm\\^2 to \\\u003C45.0 kg\u002Fm\\^2 at screening OR\n2. BMI ≥27.0 kg\u002Fm\\^2 at screening with at least 1 of the following weight-related co-morbidities: Hypertension, Dyslipidemia, Prediabetes, established Obstructive Sleep Apnea (OSA), established Coronary Artery Disease (CAD), Heart failure, established cerebrovascular disease as described in the protocol\n\nKey Exclusion Criteria:\n\n1. Previous or current diagnosis of Type 1 or Type 2 diabetes at screening\n2. Change in body weight \\>5 kg within approximately 3 months before screening as described in the protocol\n3. Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions as described in the protocol\n4. History of acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones\n5. History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2\n\nNote: Other Protocol Defined Inclusion\u002F Exclusion Criteria Apply","ALL","18 Years",{"count":117,"type":118},360,"ESTIMATED","INTERVENTIONAL",[121],"PHASE2","This study will test an experimental drug called olatorepatide (\"study drug\") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes.\n\nThe study is looking at:\n\n* What side effects the study drug might cause\n* How much study drug is in the blood at different times\n* How well the study drug works\n* What effects the study drug may have on the body at different dosing schedules\n* If the body makes antibodies to the study drug as this may cause the study drug to not work as well",[124],"Overweight or Obesity",[126,127,128,129],"Body weight","Glucagon-Like Peptide-1 (GLP-1)\u002FGastric inhibitory polypeptide (GIP) receptor agonist","Dose-finding","Control appetite","2026-08-18",{"date":132,"type":133},"2026-08-20","ACTUAL",{"date":135,"type":133},"2026-07-28",{"date":137,"type":118},"2028-01-21",{"name":5,"class":6},5]